MGMichelle Greenman

Michelle Greenman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle Greenman has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer

    by Tobias M. P. Hartwich, Stefania Bellone, Orazio De Tommasi, Sarah Ottum, Victoria Ettorre, Michelle Greenman, Namrata Sethi, Cem Demirkiran, Kevin Y. Yang, Ammal Abbasi, et al.

    Carboplatin/paclitaxel (CP) chemotherapy is the cornerstone of therapy for advanced stage ovarian cancer (OC). However, despite initial sensitivity, this regimen cannot avoid the emergence of resistance. Ixabepilone ± bevacizumab (IB) is a combination recently added to NCCN guidelines for the treatment of platinum-resistant OC. It would be desirable to identify biomarkers able to differentiate patients who are resistant to CP and IB, and biomarkers that identify which patients may benefit from IB treatment. We analyzed whole-exome-sequencing (WES) data from 49 OC patients exposed to CP, including 28 platinum-sensitive vs. 21 platinum-resistant, and 31 additional platinum-resistant patients, including 16 responders (i.e., CR/PR) vs. 15 non-responders (SD/PD) to ixabepilone ± bevacizumab. Comprehensive genetic analyses were performed to identify alterations correlated with resistance to CP and IB. WES analysis of CP responders vs. non-responders revealed differences in HRD-signatures (p < 0.05), OS (p < 0.005) and gain/loss-of-function in multiple genes associated with tumor growth/progression including but not limited to ACVR2A, INHBA, MAP3K7, ATG5, SGK1, FYN, RSPO3, NOD1 and LRRK2. WES analysis of platinum-resistant IB-treated patients revealed additional nominally significant genes and deranged pathways including gains in the DROSHA and SDHA genes in responders vs. non-responders (p < 0.05). Patients harboring HRD-signatures showed significantly higher sensitivity to CP and prolonged survival compared to HRD-negative patients. Alterations in genes associated with tumor growth/progression correlated with resistance to CP regimen and may represent novel “druggable” candidate biomarkers for the targeted treatment of CP/IB-resistant patients. Further validation in independent cohorts and preclinical experiments in CP/IB-resistant models are warranted to establish the clinical utility of these findings.

  • Open Access

    Supplementary Data 1 from A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

  • Open Access

    Supplementary Data 2 from A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

  • Open Access

    Supplementary Table 1 from A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

    Representativeness of Study Participants.

  • Open Access

    Data from A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

    Purpose:Patients with endometrial cancer who progress after chemotherapy/immunotherapy have limited treatment options. We evaluated the activity and safety of sacituzumab govitecan (SG), a Trop-2–directed antibody–drug conjugate, in patients with advanced/recurrent endometrial cancer, including carcinosarcoma. Patients and Methods:This was a phase II, two-stage, open-label, investigator-initiated trial of patients with persistent/recurrent endometrial cancer who had progressed following ≥1 prior chemotherapy. Patients received SG 10 mg/kg on days 1 and 8 every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Secondary endpoints included clinical benefit rate [CBR = complete response (CR) + partial response (PR) + stable disease ≥ 6 months], duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Trop-2 expression was analyzed by immunohistochemistry as an H-score. Results:Fifty patients were screened, and 21 enrolled during stage 1; 34 patients were screened, and 29 enrolled during stage 2; 84% (n = 42) of the patients harbored serous carcinoma, carcinosarcoma, or grade 3 endometrioid tumors. Patients received a median of two prior therapies (range, 1–4) and 50% had failed pembrolizumab/dostarlimab. At a median follow-up (range) of 11 (2.9–65.5) months, the ORR was 28% [95% confidence interval (CI), 16%–42%], including CRs (4%) and PRs (24%). The median DOR (95% CI) was 9.3 (2–12.9) months, with four still responding. The CBR was 52% (26/50). The median PFS and OS were 5.5 (95% CI, 3.7–7.4) and 17.5 (95% CI, 10.4–22.2) months, respectively. Grade 3 to 4 toxicity occurred in 88% with no attributable deaths. Mean H-scores did not predict response. Conclusions:SG demonstrated encouraging efficacy in a pretreated population that included biologically aggressive recurrent endometrial cancer. Adverse events were consistent with the known safety profile.

  • Open Access

    Supplementary Data 3 from A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

  • Open Access

    A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer

    by Alessandro D. Santin, Dana M. Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Katyayani Papatla, Aparna Kailasam, Natalia Buza, Mitchell Clark, et al.

    Purpose: Patients with endometrial cancer who progress after chemotherapy/immunotherapy have limited treatment options. We evaluated the activity and safety of sacituzumab govitecan (SG), a Trop-2–directed antibody–drug conjugate, in patients with advanced/recurrent endometrial cancer, including carcinosarcoma. Patients and Methods: This was a phase II, two-stage, open-label, investigator-initiated trial of patients with persistent/recurrent endometrial cancer who had progressed following ≥1 prior chemotherapy. Patients received SG 10 mg/kg on days 1 and 8 every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Secondary endpoints included clinical benefit rate [CBR = complete response (CR) + partial response (PR) + stable disease ≥ 6 months], duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Trop-2 expression was analyzed by immunohistochemistry as an H-score. Results: Fifty patients were screened, and 21 enrolled during stage 1; 34 patients were screened, and 29 enrolled during stage 2; 84% (n = 42) of the patients harbored serous carcinoma, carcinosarcoma, or grade 3 endometrioid tumors. Patients received a median of two prior therapies (range, 1–4) and 50% had failed pembrolizumab/dostarlimab. At a median follow-up (range) of 11 (2.9–65.5) months, the ORR was 28% [95% confidence interval (CI), 16%–42%], including CRs (4%) and PRs (24%). The median DOR (95% CI) was 9.3 (2–12.9) months, with four still responding. The CBR was 52% (26/50). The median PFS and OS were 5.5 (95% CI, 3.7–7.4) and 17.5 (95% CI, 10.4–22.2) months, respectively. Grade 3 to 4 toxicity occurred in 88% with no attributable deaths. Mean H-scores did not predict response. Conclusions: SG demonstrated encouraging efficacy in a pretreated population that included biologically aggressive recurrent endometrial cancer. Adverse events were consistent with the known safety profile.


  • Open Access

    Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor

    by Cem Demirkiran, Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias Max Philipp Hartwich, Blair McNamara, Michelle Greenman, Yang Yang-Hartwich, Elena Ratner, Niccoló G. Santin, et al.

    Low-grade-serous ovarian carcinomas (LGSOC) are rare tumors characterized by a high recurrence rate and limited treatment options. Most LGSOC are estrogen receptor (ER)-positive and demonstrate alterations in the RAS/MAPK pathway. Avutometinib is a dual RAF/MEK clamp, whereas defactinib and VS-4718 are focal adhesion kinase (FAK) inhibitors. Fulvestrant is an ER antagonist/degrader. We assessed the preclinical efficacy of fulvestrant, avutometinib + VS-4718 (FAKi), and the triple combination in a chemotherapy/aromatase inhibitor-resistant LGSOC patient-derived tumor xenograft (PDX) model. Tissue obtained from a LGSOC patient wild-type for KRAS/NRAS/BRAF mutations in progression after chemotherapy/anastrozole was transplanted into female CB17/lcrHsd-Prkdc/SCID mice (PDX-OVA(K)250). The animals were treated with either saline/control, fulvestrant, avutometinib/FAKi, or the triple combination of avutometinib/FAKi/fulvestrant. Avutometinib and FAKi were given five-days on and two-days off through oral gavage. Fulvestrant was administered subcutaneously weekly. Mechanistic studies were performed ex vivo using Western blot assays. Animals treated with the triple combination demonstrated stronger tumor growth inhibition compared to all the other experimental groups including control/saline (p < 0.001), single-agent fulvestrant (p = 0.04 from day eight and onwards), and avutometinib/FAKi (p = 0.02 from day 18). Median survival for mice treated with saline/control was 29 days while mice in all other experimental groups were alive at day 60 (p < 0.0001). Treatment was well tolerated across all experimental treatments. By Western blot, exposure of OVA(K)250 to the triple combination demonstrated a decrease in phosphorylated MEK (p-MEK) and p-ERK levels. The addition of fulvestrant to avutometinib/FAKi is well tolerated in vivo and enhances the antitumor activity of avutometinib/FAKi in a LGSOC-PDX model with acquired resistance to chemotherapy/aromatase inhibitors. These results support the clinical evaluation of avutometinib/defactinib in combination with fulvestrant or an aromatase inhibitor in patients with recurrent LGSOC.


  • Open Access

    Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

    by Niccolò G. Santin, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Natalia Buza, Tobias M.P. Hartwich, Luca Palmieri, et al.

    Phosphorylation of histone H2AX as a marker of dsDNA breaks induced from cell internalization of Dato-DΧd. A, TROP2-negative cell line END(K)34 does not show statistically significant difference in p-H2AX MFI when treated with 5 μg/mL Dato-DΧd vs. when treated with 5 μg/mL control ADC (P > 0.05). B and C, Increase in p-H2AX MFI is statistically significant when high (3+) TROP2-expressing cell lines END(K)254 and END(K)265 are treated with 5 μg/mL Dato-DΧd vs. 5 μg/mL control ADC (P = 0.0156 and P = 0.0427; *, P < 0.05). The bar graphs show normalized MFI values. Error bars indicate SEM

  • Open Access

    Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

    by Niccolò G. Santin, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Victoria M. Ettorre, Michelle Greenman, Blair McNamara, Natalia Buza, Tobias M.P. Hartwich, Luca Palmieri, et al.

    Flow cytometry–based cytotoxicity assay. Determination of Dato-DXd and control ADC IC50 (mean SEM) in the tested cell lines. A, Cell line with 0 TROP2 expression [i.e., END(K)34] showed no difference in the IC50 of Dato-DXd and control ADC. B and C, Cell lines with high TROP2 expression [3+; i.e., END(K)254 and END(K)265] demonstrated significantly lower IC50 for Dato-DXd when compared with control ADC (P < 0.05)